Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | ESR1 | P03372 | 6/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.52 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13797574 | 1.00 | LMNA (0.67) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL13768825 | 1.00 | LMNA (0.67) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL12904926 | 1.00 | LMNA (0.67) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL16572814 | 0.86 | ESR1 (0.77) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL12942778 | 0.84 | LMNA (0.68) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL6026301 | 0.84 | LMNA (0.68) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL13797577 | 0.84 | LMNA (0.68) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL17995240 | 0.83 | LMNA (0.66) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| SCHEMBL15979561 | 0.83 | LMNA (0.66) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 | |
| Epimestrol SCHEMBL554257 | 0.82 | ESR1 (0.75) | LMNAHSD17B10ESR1ESR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987239-B2 | 19-nor-steroid derivatives with a 15α,16α-methylene group and a saturated 17,17-spirolactone ring, use thereof, and medicaments containing said derivatives | Bayer Intellectual Property GbmH (DE) | 2015-03-24 | — | — | US | disclosed |
| EP-2238149-B1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER IP GMBH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8623850-B2 | 15, 16-methylene-17-(1′-propenyl)-17,3′-oxidoestra-4-en-3-one derivative, use thereof, and medicament containing said derivative | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-16 | — | — | US | disclosed |
| EP-2238148-B1 | 15,16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| EP-2238150-B1 | 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110015162-A1 | 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid Y-lactone derivative, use thereof and medicinal products containing the derivative | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110003779-A1 | 15, 16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | BAYER SCHERING PHARMA AKTEINGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| EP-2238150-A1 | 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID y-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009083269-A1 | 15,16-METHYLENE-17-HYDROXY-19-NOR-21-CARBOXYLIC ACID γ-LACTONE DERIVATIVE, USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003779-A1 | 15, 16-METHYLENE-17-(1'-PROPENYL)-17,3'-OXIDOESTRA-4-EN-3-ONE DERIVATIVE , USE THEREOF, AND MEDICAMENT CONTAINING SAID DERIVATIVE | CYP19A1, NR5A1, SRD5A1 | LMNA 827/4885HSD17B10 328/4885ESR1 31/4885 |
| US-20110015162-A1 | 15,16-Methylene-17-hydroxy-19-nor-21-carboxylic acid-steroid Y-lactone derivative, use thereof and medicinal products containing the derivative | CYP17A1, CYP19A1, HSD17B7 | LMNA 430/4885HSD17B10 89/4885ESR1 47/4885 |
| US-20100311702-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15ALPHA, 16ALPHA-METHYLENE GROUP AND A SATURATED 17, 17-SPIRO-LACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | LMNA 2564/4885HSD17B10 52/4885ESR1 112/4885 |
| US-20130123219-A1 | 19-NOR-STEROID DERIVATIVES WITH A 15a,16a-METHYLENE GROUP AND A SATURATED 17,17-SPIROLACTONE RING, USE THEREOF, AND MEDICAMENTS CONTAINING SAID DERIVATIVES | HSD17B7, CYP17A1, NR3C2 | LMNA 1657/4885HSD17B10 46/4885ESR1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.